Aligos Therapeutics (ALGS) Cash from Financing Activities (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Cash from Financing Activities came in at $220000.0 in Q2 2026, up 224.29% on a YoY basis from $67839.7 in Q2 2025, and up 454.84% quarter-over-quarter from -$62000.0 in Q1 2026.
Powered by 
Analysis
Aligos Therapeutics (ALGS) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has reported Cash from Financing Activities for 8 consecutive years, with $220000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities rose 224.29% year-over-year to $220000.0; the trailing twelve-month figure through Jun 2026 stood at $228000.0 (down 99.78% YoY), and the FY2025 full-year result was $101.6 million, up 28529.58% from the prior year.
- Cash from Financing Activities advanced to $220000.0 in Q2 2026 per ALGS's latest filing, from -$62000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $101.7 million in Q1 2025 and bottomed at -$177000.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $10.6 million across 5 years, with a median of $41000.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities tumbled 1800.0% in 2024, then jumped 535584.21% in 2025.
- Over 5 years, Cash from Financing Activities stood at $121000.0 in 2022, then surged by 72574.38% to $87.9 million in 2023, then slumped by 99.89% to $97000.0 in 2024, then increased by 26.8% to $123000.0 in 2025, then soared by 78.86% to $220000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $220000.0, -$62000.0, and $123000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Aligos Therapeutics | 54.92 Mn | 24.48 Mn | - | 220,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 220,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | -53,000.00 |
| Jun 30, 2025 | -177,000.00 |
| Mar 31, 2025 | 101.74 Mn |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Dec 31, 2023 | 87.94 Mn |
| Sep 30, 2023 | -21,000.00 |
| Jun 30, 2023 | 414,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Dec 31, 2022 | 121,000.00 |
| Sep 30, 2022 | -19,000.00 |
| Jun 30, 2022 | 83,000.00 |
| Mar 31, 2022 | -21,000.00 |
| Dec 31, 2021 | 552,000.00 |
| Sep 30, 2021 | 77.95 Mn |